The Management of Amyotrophic Lateral Sclerosis:
A Guide to Enhance Outcomes for Managed Care and Payer Professionals

• Release Date: July 1, 2022
• Expiration Date: January 31, 2024
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

Expert Faculty Author:

Terry D. Heiman-Patterson, MD Professor of Neurology Lewis Katz School of Medicine at Temple University Director Temple MDA/ALS Center of Hope Click here for biography James T. Kenney, RPh, MBA Founder and President JTKENNEY, LLC Click here for biography Michael Kobernick, MD, MS, MS-PopH, CPE Senior Medical Director – Health Plan Business Blue Cross Blue Shield of Michigan Lecturer Jefferson College of Population Health Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

Statement of Need/Program Overview
Amyotrophic lateral sclerosis (ALS) is characterized by a devastating disease course with significant clinical, economic, and humanistic burden. These disease-related challenges associated with ALS are compounded for managed care and other payer professionals who are tasked with managing rising health care expenditures and the specialty drug trend, as well as affiliated case managers who act as a conduit through which patients access specific components of care. The expert faculty will present and discuss recent insights into the management of patients who may benefit from effective therapeutic intervention for ALS via case-based discussions. In addition, the faculty panel, including managed care experts, will review important, relevant therapeutic category information.

Educational Objectives
After completing this activity, the participant should be better able to:

• Characterize the clinical, economic, and humanistic burden of ALS in terms of health care resource utilization, indirect costs, and member quality of life
• Outline the interdisciplinary components of effective coordinated care interventions in the management of ALS
• Assess the value of appropriate, evidence-based drug therapy for slowing disease progression and minimizing direct expenditures in other categories
• Characterize the adverse effect of excess cost-sharing and prohibitive coverage criteria on patient access and adherence
• Implement medical and pharmacy benefit design strategies that improve access to therapy and manage costs with evidence-based clinical care for ALS

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit
Medical Education Resources designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Medical Education Resources designates this activity for a maximum of 1.0 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hours.

Pharmacy Credit

Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0003680-9999-22-011-H01-P
This activity is certified as Knowledge-based CPE.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Mitsubishi Tanabe Pharma America, Inc. and Amylyx. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period July 1, 2022, through January 31, 2024, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet